Physician profile

Benjamin Zaremski

Cardiovascular Disease · New York, NY

NPI 1912080524

$3,931.08

in general payments reported to CMS, 2019-2025

19 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Boehringer Ingelheim Pharmaceuticals, INC. $846.42 2019-2022
Biotronik INC. $557.87 2019-2022
Janssen Pharmaceuticals, INC $534.60 2019-2022
Amgen INC. $389.83 2019-2022
Astrazeneca Pharmaceuticals LP $316.61 2019-2021
Novartis Pharmaceuticals Corporation $305.67 2019-2021
Amarin Pharma, INC. $216.96 2019-2021
Pfizer INC. $206.05 2019-2022
Novo Nordisk INC $109.09 2021-2022
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $108.28 2020-2022
Takeda Pharmaceuticals U.S.A., INC. $93.90 2019-2021
E.R. Squibb & Sons, L.L.C. $69.73 2019-2022
Edwards Lifesciences Corporation $39.65 2019
Esperion Therapeutics, INC. $29.91 2021
Regeneron Healthcare Solutions, INC. $27.63 2019
Show all 19 companies
CompanyGeneral paymentsYearsTop products
Daiichi Sankyo INC. $24.79 2019
Sanofi-Aventis U.S. LLC $24.54 2019
Metuchen Pharmaceuticals $16.62 2020
Merck Sharp & Dohme LLC $12.93 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Benjamin Zaremski

$3,931.08

in general payments reported 2019-2025

Years
2019-2022
Top company
Boehringer Ingelheim Pharmaceuticals, INC.

https://glasscript.com/doctor/41545/benjamin-zaremski

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.